Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Hormone therapy that has saved hundreds of thousands from breast cancer. | Breast cancer hormone therapy after menopause; also a fertility drug. |
| Body system | Cancer | Cancer |
| Drug class | Selective oestrogen receptor modulators | Aromatase inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription onlyWHO essential medicine |
| Main uses | Hormone-receptor-positive breast cancer (pre- and post-menopause), Breast cancer prevention in high risk, Male breast cancer | Hormone-receptor-positive breast cancer after menopause, Ovulation induction in PCOS (off-label) |
| How it works | Stops oestrogen fuelling breast cancer cells. | Shuts down oestrogen production after menopause. |
| Starts working | — | — |
| Half-life | 5–7 days | About 2 days |
| Typical adult dose | 20 mg once a day for 5–10 years. | Breast cancer: 2.5 mg once a day for 5–10 years. |
| Forms | Tablet, Oral solution | Tablet |
| Common side effects | Hot flushes, Vaginal discharge, Irregular periods, Mood changes | Joint and muscle pain, Hot flushes, Fatigue, Raised cholesterol |
| Serious side effects | Blood clots, Womb cancer (post-menopause), Stroke, Cataracts | Bone loss and fractures, Heart problems (rare) |
| Don't take if | Pregnancy; History of blood clots (caution); Taking potent CYP2D6 inhibitors (paroxetine, fluoxetine) — reduces effect; Undiagnosed vaginal bleeding | — |
| Alcohol | Usually no problem in moderation. No specific interaction. | — |
| Pregnancy | Usually avoidedCan harm the fetus; avoid pregnancy for 2 months after stopping. | Usually avoidedContraindicated in pregnancy (fertility use is before conception). |
| Breastfeeding | Usually avoidedAvoid. | — |
| In use since | 1973 | 1996 |
| Brand names | United States: SoltamoxUnited Kingdom: Nolvadex-D, SoltamoxIndia: Tamodex, Mamofen | United States: FemaraUnited Kingdom: FemaraIndia: Letroz, Femara, Letoval |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H | — |
| ATC code | L02BA01 | L02BG04 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker